Deal Structure Guide
What Is a Contingent Value Right (CVR)?
A mechanism for bridging valuation gaps in biopharma M&A — and why the structure matters more than the headline number.
What a CVR actually is
A contingent value right is a contractual instrument — typically issued as part of an M&A transaction — that entitles the holder to receive additional consideration if specified future events occur. In biopharma, those events are almost always clinical or regulatory milestones: an FDA approval, a Phase 3 readout meeting its primary endpoint, or a commercial sales threshold.
The buyer pays an upfront price for the company and issues CVRs representing the portion of value both sides cannot agree on today. If the milestone is achieved, the CVR pays out. If not, the holder receives nothing beyond the upfront consideration.
CVRs are distinct from earnouts. An earnout is typically tied to financial performance — revenue targets, EBITDA thresholds — and sits within the purchase agreement. A CVR is usually a separately traded instrument (often registered under SEC regulations), with its own trustee, transfer agent, and, in many cases, public market liquidity. The structural difference matters: CVRs create tradeable optionality; earnouts create contractual obligations with dispute risk.
How CVRs work in practice
The mechanics follow a consistent pattern across most biopharma transactions.
At signing, the acquirer and target agree on: (1) the upfront consideration — cash, stock, or a combination; (2) the CVR trigger event, defined with clinical precision; (3) the CVR payout amount, either fixed or formulaic; (4) the expiration window, typically 3-7 years; and (5) diligence obligations — whether the acquirer is contractually required to pursue the triggering event.
Once the transaction closes, each shareholder receives CVRs alongside their upfront consideration, usually on a per-share basis. If the trigger event occurs within the specified window, the CVR agent distributes the additional payment. If the window expires without the trigger, the CVRs expire worthless.
The most critical design element is the diligence clause. Non-transferable CVRs without binding development obligations give the acquirer significant optionality — they can de-prioritize or shelve the program with no financial consequence beyond the upfront already paid. Sellers who accept this structure are effectively granting the buyer a free option on their asset's future value.
What the data shows
Across the biopharma M&A transactions in our database, CVR structures reveal several patterns that sellers should internalize before entering negotiations.
CVR achievability is lower than headline numbers suggest. Roughly 35-40% of CVRs issued since 2018 have paid out at all. The achievability rate drops further when filtered to clinical-stage triggers — Phase 3 readout CVRs achieve at approximately 28%, while regulatory approval CVRs land closer to 45%, reflecting the lower residual risk once Phase 3 data is in hand.
The median CVR payout, as a percentage of total deal consideration, sits at approximately 22%. That means the typical CVR-bearing deal allocates roughly one-fifth of total value to a contingent instrument that pays out less than half the time.
Geographic variation exists. China-to-West transactions have used CVR structures more aggressively since 2023, with CVR components representing up to 35% of total deal value in cross-border acquisitions. The higher contingent allocation reflects the additional regulatory uncertainty of bringing Chinese-originated assets through Western approval pathways.
You can explore comparable CVR structures using Solidus, our deal benchmarking platform at calculator.ambrosiaventures.co.
What most companies get wrong
The first mistake is treating the CVR as found money. Boards that negotiate an upfront of $25 per share plus a $5 CVR often tell their shareholders the deal is worth $30. It is not. The CVR is worth its probability-adjusted value, which — for a Phase 3-triggered CVR — may be closer to $1.40.
The second mistake is ignoring diligence obligations. A CVR without a contractual requirement for the acquirer to conduct the triggering trial is economically closer to zero than to face value. The acquirer controls the program post-close. If their portfolio priorities shift, your CVR becomes an unfunded obligation with no enforcement mechanism.
The third mistake is accepting a narrow trigger window. A 24-month CVR on a program that requires 18 months of patient enrollment leaves virtually no margin for the inevitable delays that characterize clinical development. Sellers should model realistic timelines — including FDA review cycles and potential complete response letters — and insist on windows that accommodate them.
The fourth mistake is conflating tradeable CVRs with non-tradeable ones. Tradeable CVRs give shareholders the ability to monetize their contingent consideration immediately at market prices. Non-tradeable CVRs lock shareholders into a binary outcome with no interim liquidity.
Related Insights
Further reading from our research.
Bring us your transaction.
We’ll meet you at peer level — anywhere in the world.